Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg

Latsuzbaia, Ardashel; Arbyn, Marc; Tapp, Jessica; Fischer, Marc; Weyers, Steven; Pesch, Pascale; Mossong, Joël

doi:10.1016/j.canep.2019.101593

Cited by 20 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current preventive strategies, which include diagnostics and vaccination programs with the current HPV vaccines (2-, 4-, and 9-valent vaccines) and, in particular, the difficulties linked to their implementation in certain regions, is another aspect that explains the uneven distribution of HPV-associated diseases, specifically found to be higher in less developed regions. Developed regions, including Australia, Europe, and America, where at least two of the three current HPV vaccines have been introduced, have reported a decrease in the incidence of HPV-related HPV infections, along with an absence of adverse effects (49,121,(140)(141)(142)(143). The success of the vaccination program lies in the fact that in these developed countries, the HPV-related disease diagnosis rate has increased, access to health care is easier, vaccination programs are well-followed until completion, and the L1 protein used in the vaccines is from Caucasian intratypic variants.…”

Section: Discussionmentioning

confidence: 99%

“…Gardasil, Cervarix, and Gardasil9 are highly effective vaccines approved in 2006, 2009, and 2014, respectively, by the Food and Drug Administration (136,137) to prevent HPV infections and related diseases (132,133,138,139). Indeed, in Australia and Luxembourg, a significant reduction in the burden of HPV infections and related diseases was observed (140,141) after the introduction of 2vHPV and/or 4vHPV in vaccination programs. Recently, Rossi et al (142) reported that the three vaccines, particularly the 9vHPV, offer extensive and effective protection against AGW, CIN-PIN2/3, and some cancers.…”

Section: Hpv Preventive Strategies: Challengesmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation

Kombe

Zahid

et al. 2021

Front. Public Health

314

276

View full text Add to dashboard Cite

Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women, human papillomavirus (HPV) is currently the most common pathogen responsible for female cancers. Moreover, HPV infection is associated with many other diseases, including cutaneous and anogenital warts, and genital and upper aerodigestive tract cancers. The incidence and prevalence of these pathologies vary considerably depending on factors including HPV genotype, regional conditions, the study population, and the anatomical site sampled. Recently, features of the cervicovaginal microbiota are found to be associated with the incidence of HPV-related diseases, presenting a novel approach to identify high-risk women through both blood and cervical samples. Overall, the HPV repartition data show that HPV infection and related diseases are more prevalent in developing countries. Moreover, the available (2-, 4-, and 9-valent) vaccines based on virus-like particles, despite their proven effectiveness and safety, present some limitations in terms of system development cost, transport cold chain, and oncogenic HPV variants. In addition, vaccination programs face some challenges, leading to a considerable burden of HPV infection and related diseases. Therefore, even though the new (9-valent) vaccine seems promising, next-generation vaccines as well as awareness programs associated with HPV vaccination and budget reinforcements for immunization are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hpv Preventive Strategies: Challengesmentioning

confidence: 99%

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation

Kombe

Zahid

et al. 2021

Front. Public Health

314

276

View full text Add to dashboard Cite

show abstract

“…Data from the end-of-study analysis of PATRICIA illustrated consistent vaccine efficacy against persistent infection and CIN2+ (with or without HPV16/18 co-infection) across cohorts for HPV33, HPV31, HPV45, and HPV51 [23]. Furthermore, a recent publication [24] suggested that cross-protection is higher in 2-valent vaccine recipients compared to 4-valent vaccine recipients. These findings are in line with the recent Cochrane review [25] which also showed similar protection of 2-valent and 4-valent vaccines against cervical pre-cancers related to types 16/18, but concluded that the 2-valent vaccine offered better protection against cervical pre-cancers overall.…”

Section: Discussionmentioning

confidence: 87%

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

Valasoulis

Pouliakis

Michail

et al. 2020

Cancers

View full text Add to dashboard Cite

The objective of this study was to investigate the hypothesis that HPV vaccination administered in patients with low-grade (LG) cytology shortly after an initial colposcopic assessment could prospectively alter HPV-related biomarkers. This was a prospective pilot observational study involving women attending a colposcopy clinic for evaluation of abnormal LG cytology that were advised to undergo HPV vaccination and proceeded accordingly. These women were compared with a matched unvaccinated group. Women requiring cervical biopsies or CIN treatment were excluded. Intervention: A full three-dose HPV vaccination was undertaken with either the 2-valent or the 4-valent anti-HPV VLP vaccine. LBC samples were obtained prior and after the completion of the vaccination regimen and tested for HPV DNA genotyping (CLART-2 HPV test) and E6 and E7 mRNA (NASBA technique). Results: Alterations of HPV-related biomarkers at a colposcopy reassessment appointment 12 months later. Analysis: The p-values, relative risk (RR), absolute relative risk (ARR), number needed to treat (NNT) and 95% confidence intervals for each biomarker in each group were assessed. Results: A total of 309 women were included in the analysis. One hundred fifty-two women received the vaccine. HPV vaccination reduced in a statistically significant manner (p < 0.05) HPV DNA positivity rates for genotypes 16, 18, and 31, RR = 1.6 (95% CI: 1.1 to 2.3), RR = 1.7 (95% CI: 1.1 to 2.8), and RR = 1.8 (95% CI: 1.0 to 2.9), in women who only tested DNA-positive for HPV16, 18, and 31 genotypes, respectively, prior to vaccination. A less pronounced, statistically insignificant reduction was shown for women who tested positive for both HPV DNA and mRNA E6 and E7 expression for HPV16, 18, and 33 subtypes. Statistically significant reduction in HPV mRNA positivity was solely documented for genotype 31 (p = 0.0411). Conclusions: HPV vaccination appears to significantly affect the rates of HPV16, 18, and 31 DNA-positive infections in the population testing HPV DNA-positive for the aforementioned genotypes. The above findings deserve verification in larger cohorts.

show abstract

“…Cigarette smoking was included in both models, since previous studies have shown that smoking was associated with unsafe sexual behaviour (Hansen et al, 2010). Models were adjusted for nationality and age, since both variables affected vaccination uptake (Latsuzbaia et al, 2019;Latsuzbaia et al, 2018). Since the effect of an exposure on an outcome can be masked by intermediate and confounding variables (Westreich & Greenland, 2013), to estimate the total effects size of the variables of interests, we studied each sexual behaviour variable in separate models adjusting for smoking, nationality and age.…”

Section: Discussionmentioning

confidence: 99%

“…The primary aim of our study was to investigate whether HPV vaccination was associated with unsafe sexual behaviour in sexually active, healthcare seeking adult women. It is a secondary analysis of sexual behaviour data collected for a vaccine surveillance study conducted in Luxembourg between November 2015 and December 2017 (Latsuzbaia et al, 2019). Additionally, we assessed assortativity by age of sexual mixing in this study population.…”

Section: Introductionmentioning

confidence: 99%

HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg

Soudeyns

Speybroeck

Brisson

et al. 2020

PeerJ

Self Cite

View full text Add to dashboard Cite

Introduction Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Despite recommendations for HPV vaccination of young women from health authorities, parental concerns were raised whether vaccination could induce unsafe sexual behaviour in young women. Therefore, the primary aim of this study was to investigate if HPV vaccination in healthcare seeking adult women in Luxembourg was associated with unsafe sexual behaviour. Methods Seven hundred twenty-nine women (mean age = 22.5; range 18–43 years) were recruited either at Luxembourg family planning centres or at private gynaecology practices. All participants completed a questionnaire on vaccination status and sexual behaviour. Poisson and logistic regressions were used to study the association between sexual behaviour and vaccination status (N = 538). Both models were restricted to women younger than 26 years, since the first cohort being vaccinated would be 25 years old at the time of sampling. Assortativity of sexual mixing by age was also assessed for further transmission modelling for women <30 years reporting age of last/current sexual partner (N = 649). Women older than 29 years were excluded from the assortativity analysis due to restricted sample size. Results In total, 386/538 (71.8%) of participants reported receiving HPV vaccine. Vaccination uptake significantly varied by nationality and was higher in Portuguese 112/142 (78.9%) and in Luxembourgish 224/313(71.6%) residents, and lower in residents of other nationalities 50/83 (60.2%) (p = 0.011). HPV vaccination was not associated with unsafe sexual behaviour such as shorter relationship duration with current or last sexual partner (odds ratio (OR) = 1.05, 95% CI [0.94–1.16]), younger age of sexual debut (OR = 1.00, 95% CI [0.88–1.14]), increased number of lifetime sexual partners (OR = 0.95, 95% CI [0.87–1.03), higher age difference with sexual partner (OR = 1.01, 95% CI [0.95–1.08]), condom use (OR = 0.97, 95% CI [0.60–1.56]), nor with other factors like smoking (OR = 0.73, 95% CI [0.47–1.15]) and nationality. HPV vaccination was only associated with younger age (OR = 0.84, 95% CI [0.75–0.94]). Relationship duration, age of sexual debut, age difference with sexual partner, smoking, age and non-Portuguese foreign nationality were predictors of number of lifetime sexual partners. Assortativity analysis revealed that young women chose sexual partners who were 2.3 years older on average. Conclusions Our study found no association between unsafe sexual behaviour and HPV vaccination.

show abstract

Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg

Cited by 20 publications

References 37 publications

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg

Contact Info

Product

Resources

About